ACAD
Price
$26.53
Change
-$0.33 (-1.23%)
Updated
Jan 15 closing price
Capitalization
4.49B
45 days until earnings call
Intraday BUY SELL Signals
AURA
Price
$5.11
Change
-$0.15 (-2.85%)
Updated
Jan 15 closing price
Capitalization
324.5M
74 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACAD vs AURA

Header iconACAD vs AURA Comparison
Open Charts ACAD vs AURABanner chart's image
ACADIA Pharmaceuticals
Price$26.53
Change-$0.33 (-1.23%)
Volume$998.18K
Capitalization4.49B
Aura Biosciences
Price$5.11
Change-$0.15 (-2.85%)
Volume$115.63K
Capitalization324.5M
ACAD vs AURA Comparison Chart in %
View a ticker or compare two or three
VS
ACAD vs. AURA commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and AURA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (ACAD: $26.53 vs. AURA: $5.11)
Brand notoriety: ACAD and AURA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 71% vs. AURA: 60%
Market capitalization -- ACAD: $4.49B vs. AURA: $324.5M
ACAD [@Biotechnology] is valued at $4.49B. AURA’s [@Biotechnology] market capitalization is $324.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $111.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileAURA’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • AURA’s FA Score: 1 green, 4 red.
According to our system of comparison, ACAD is a better buy in the long-term than AURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 3 TA indicator(s) are bullish while AURA’s TA Score has 4 bullish TA indicator(s).

  • ACAD’s TA Score: 3 bullish, 5 bearish.
  • AURA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ACAD and AURA are a bad buy in the short-term.

Price Growth

ACAD (@Biotechnology) experienced а -1.41% price change this week, while AURA (@Biotechnology) price change was -0.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +2.38%, and the average quarterly price growth was +41.99%.

Reported Earning Dates

ACAD is expected to report earnings on Mar 02, 2026.

AURA is expected to report earnings on Mar 31, 2026.

Industries' Descriptions

@Biotechnology (+0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($4.49B) has a higher market cap than AURA($325M). ACAD YTD gains are higher at: -0.674 vs. AURA (-6.239). ACAD has higher annual earnings (EBITDA): 108M vs. AURA (-112.21M). ACAD has more cash in the bank: 847M vs. AURA (162M). AURA has less debt than ACAD: AURA (17.8M) vs ACAD (54.8M). ACAD has higher revenues than AURA: ACAD (1.05B) vs AURA (0).
ACADAURAACAD / AURA
Capitalization4.49B325M1,381%
EBITDA108M-112.21M-96%
Gain YTD-0.674-6.23911%
P/E Ratio17.12N/A-
Revenue1.05B0-
Total Cash847M162M523%
Total Debt54.8M17.8M308%
FUNDAMENTALS RATINGS
ACAD: Fundamental Ratings
ACAD
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
26
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
77
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACADAURA
RSI
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
77%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 10 days ago
76%
Bullish Trend 25 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signal:
Gain/Loss:
AURA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSVAX20.190.26
+1.30%
PGIM Quant Solutions Small-Cap Val A
TSCHX20.840.23
+1.12%
Nuveen Quant Small Cap Equity I
BOSOX17.620.16
+0.92%
Boston Trust Walden Small Cap
PRUFX107.160.18
+0.17%
T. Rowe Price Growth Stock I
RAGHX29.87-0.12
-0.40%
Virtus KAR Health Sciences A

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with STTK. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-1.23%
STTK - ACAD
39%
Loosely correlated
-5.50%
RXRX - ACAD
38%
Loosely correlated
-4.33%
AURA - ACAD
38%
Loosely correlated
-2.85%
VCYT - ACAD
36%
Loosely correlated
-3.42%
MIRM - ACAD
36%
Loosely correlated
+1.84%
More

AURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AURA has been loosely correlated with NUVL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AURA
1D Price
Change %
AURA100%
-2.85%
NUVL - AURA
50%
Loosely correlated
-1.56%
DSGN - AURA
48%
Loosely correlated
-4.49%
XNCR - AURA
47%
Loosely correlated
-8.58%
VIR - AURA
46%
Loosely correlated
-9.09%
RGNX - AURA
46%
Loosely correlated
-7.96%
More